Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 4334
Journal of Alzheimers Disease & Parkinsonism received 4334 citations as per Google Scholar report
Journal of Alzheimers Disease & Parkinsonism peer review process verified at publons
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- JournalTOCs
- China National Knowledge Infrastructure (CNKI)
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Multitarget therapies in the context of the aged associated oxidative stress induced cellular and subcellular and vascular hypoperfusion and mitochondrial DNA deletion during the development and maturation of Alzheimer disease: past, present and future
11th International Conference on Vascular Dementia
Gjumrakch Aliev
“GALLY” International Biomedical Research Institute Inc., USAUniversity of Atlanta, Atlanta, USARussian Academy of Sciences, Russia
Posters & Accepted Abstracts: J Alzheimers Dis Parkinsonism
Abstract
Stroke and arteriosclerosis with neurological consequences such as Alzheimer disease (AD) are two leading causes of ageassociated disability, dementia, and death. AD is now the sixth-leading cause of death in the United States. In the US, AD is estimated to affect 4 million people (rising steeply from <1% of the population aged 65 to 40% of those aged 90) and costs $600 billion per year, which is equivalent to the total cost of stroke, heart disease, and cancer combined. Overall, there are no effective strategies for determining and controlling this devastating disease. Because AD is a multifactorial pathology and the development of new multitarget neuroprotective drugs is promising and attractive.Biography
